Estrella Immunopharma Inc. (ESLA)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $22.36M
Last updated: Nov 17, 2026 at 11:05 AM ET
Estrella Immunopharma Inc. (ESLA) Stock Forecast
Analysts expect Estrella Immunopharma (ESLA) to earn -$0.29 per share in the fiscal year ending Dec 31, 2026. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 0 down. For the fiscal year ending Dec 31, 2027, the EPS consensus is -$0.32.
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a larger loss.
- Fiscal year ending Dec 31, 2026
- -$0.29
- EPS consensus
- Fiscal year ending Dec 31, 2027
- -$0.32
- EPS consensus
- Next report
- Mar 16, 2027
- Estimated
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$0.29 | -$0.29 to -$0.29 | 1 |
| Dec 31, 2027 | -$0.32 | -$0.32 to -$0.32 | 1 |
Quarterly Estimates
| Quarter ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$0.07 | -$0.07 to -$0.07 | 3 |
Estimate Revisions
Across the 2 periods below, the last 30 days brought 2 upward and 0 downward EPS revisions. Raises outnumber cuts in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 1 | 0 |
| Fiscal year ending Dec 31, 2027 | 1 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$0.39.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$0.29 | -$0.39 | -$0.39 | -$0.39 | -$0.39 | N/A |
| Fiscal year ending Dec 31, 2027 | -$0.32 | -$0.32 | -$0.32 | -$0.32 | -$0.32 | N/A |
Frequently Asked Questions About ESLA
What is the ESLA stock forecast?
Consensus analyst estimates put Estrella Immunopharma's EPS at -$0.29 for the fiscal year ending Dec 31, 2026.
What EPS do analysts expect from ESLA next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.29, with estimates from -$0.29 to -$0.29 from 1 analyst. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.32, with estimates from -$0.32 to -$0.32 from 1 analyst.
How many analysts cover ESLA?
1 analyst estimates EPS for Estrella Immunopharma for the fiscal year ending Dec 31, 2026.
ESLA pages: Overview, Earnings, Forecast, Financials, Competitors